In $900M+ deal, rare disease biotechs team up on RNA therapies for CNS developmental disorders

Max Gelman

Senior Editor

Two biotechs that have built their reputations in rare disease research signed a new collaboration Monday morning aiming to develop three new RNA-based therapies. And …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In $900M+ deal, rare disease biotechs team up on RNA therapies for CNS developmental disorders

Max Gelman

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

FDA lifts hold on Entrada's Duchenne drug after two years

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

How AI can address ongoing challenges in the life sciences industry

In $900M+ deal, rare dis­ease biotechs team up on RNA ther­a­pies for CNS de­vel­op­men­tal dis­or­ders

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

In $900M+ deal, rare disease biotechs team up on RNA therapies for CNS developmental disorders